EMA
approval
· 2026-01-30
EMA Authorised: Trisenox (arsenic trioxide) — Teva B.V.
Summary
The European Medicines Agency has authorised Trisenox (arsenic trioxide) by Teva B.V. for use in acute promyelocytic leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Leukemia, Promyelocytic, Acute. MAH: Teva B.V.. Decision date: 15/01/2026